BACKGROUND: Effective hemostasis is mandatory for brain tumor surgery. Microporous polysaccharide hemosphere (MPH) powder, a white powder compounded from potato starch, was recently introduced for surgical and emergency application. OBJECTIVE: To evaluate the safety and efficacy of MPHs in brain tumor surgery. METHODS: Thirty-three patients (mean age, 58 years; range, 22-84 years) underwent microsurgical brain tumor resection. Final hemostasis was performed by topical application of MPHs, video recorded, and subsequently analyzed. Blood samples were taken before surgery, before application of hemospheres, and postoperatively. Volume measurements of the tumor, resection cavity, and postoperative hematoma were done on magnetic resonance imaging and computed tomography scans. Clinical examinations focused on neurological outcome, complications, and allergic reactions. RESULTS: Effective hemostasis was achieved by exclusive use of MPHs in 32 patients. In 1 patient, a single arterial bleeding underwent additional bipolar electrocauterization. Mean operative time was 156.8 minutes (range, 60-235 minutes). Hemostasis with MPHs required 57 seconds (mean; range, 8-202 seconds). Subjective neurosurgeons' ranking of the hemostasis effect indicated excellent satisfaction. For the first 3 months, there was no hemospheres-related postoperative neurological worsening, no signs of allergic reaction, and no embolic complications. Early postoperative and 3-month follow-up magnetic resonance imaging and computed tomography scans excluded any expansive bleeding complication. As early as postoperative day 1, MPHs were no longer detected. There was no tumor mimicking contrast enhancement. CONCLUSION: In neurosurgery, MPHs allow fast and effective minimally invasive hemostasis. In this small case series, no adverse reactions were found.
Clinically, MPHs have provided excellent results in endoscopic nasal sinus surgery, 1,2,7 dermatologic surgery, 5, 8 and laparoscopic surgery. 6 In these studies, rapid and effective hemostasis was achieved. There were no severe adverse events or specific postoperative complications. At present, the main areas of application are in emergency medical services and the armed forces.
The excellence results of MPHs in other surgical disciplines, the advantages over other hemostatic agents in experimental studies, and the inexpensive price make the substance potentially well suited for neurosurgical use. No previous clinical experiences in neurosurgery exist.
MATERIALS AND METHODS

Study Design
The aim of this clinical study was to evaluate MPHs to obtain hemostasis in brain tumor surgery. To achieve this goal, hemostasis during the tumor procedure was achieved by standard electrocautery techniques. At the end of tumor resection, either after complete removal of the tumor mass or after decompression of the tumor, which was considered the goal of surgery, MPHs were used for final hemostasis without additional topical agents or electrocautery. The procedures were done by 5 skilled microsurgical neurosurgeons to achieve an optimum of comparability for operative technique and operating time. The operation and application results were accurately documented and analyzed. Blood samples were taken before, during (immediately before MPH application), and after surgery. Clinical history was taken; neurological examination and neuroradiological imaging were performed preoperatively and postoperatively; and follow-up examination, including neuroimaging, was done 3 months after hospital discharge.
Description of the Absorbable Hemostat MPHs
Microporous polysaccharide hemospheres are intended for application to surgical wound sites as an absorbable hemostat. It is a 100% plantbased polysaccharide. The fine, dry, sterilized white powder contains no animal or human components. The powder consists of hydrophilic microporous particles synthesized by cross-linking purified potato starch through a proprietary process. Microporous polysaccharide hemospheres are biocompatible, nonpyrogenic, and absorbed within 24 to 48 hours. The mechanism of action is like that of a hydrophilic molecular sieve ( Figure 1 ): Fluid is absorbed, and platelets, red blood cells, and blood proteins are concentrated on the particle surfaces to form a gelled matrix. This gel enhances normal clotting reactions and creates stable hemostatic plugs. This mechanism is almost independent of the patient's coagulation status.
The medical device, MPH (Arista-AH, Medafor, Inc), has been approved for use in human surgery by the regulatory authorities in Germany and in the United States since 2006. Although its application in neurosurgery and ophthalmology has been excluded in the United States, the device is permitted for neurosurgical use in Germany. In Germany, the device is not regarded as a medical drug but as a medical device like an ultrasonic aspirator or a neuronavigational system. Because the Arista-AH device is permitted for neurosurgical application in Germany, no permission by the local ethical committee was acquired. The price for 1 g Arista-AH is around 60V in Germany. FIGURE 1. Schematic drawing of microporous polysaccharide hemospheres (MPHs; Arista-AH) and their mechanism of hemostasis action. A, MPH particle (white ball) acts as a molecular sieve, absorbing the fluid (blue arrows) and concentrating platelets, red blood cells, and blood proteins on the surface of the particles. B, brain tumor resection cavity filled with MPH particles.
Surgical Application
Thirty-three patients suffering from glioma, meningioma, or brain metastasis underwent microsurgical tumor resection. Microporous polysaccharide hemospheres (Arista-AH; packages of 1 or 3 g) were applied via a sterile malleable and disposable applicator (FlexiTip, Medafor, Inc) to the resection cavity to stop bleeding after complete or partial microsurgical tumor resection (Figure 2A through 2C) . The amount of the applied MPHs was not predefined in the study design; it depended solely on the individual preference of the performing surgeon. To evaluate the effect and the optimum dose, the applied volume and the time duration for achieving hemostasis were documented and video recorded (Video 1, Supplemental Digital Content 1, http://links.lww.com/NEU/A395, which shows the microsurgical resection in patient 14). In the microsurgical resection of an enlarged glioblastoma multiforme in patient 14, complete hemostasis was achieved in 332 seconds by application of MPHs. No additional topical hemostat or electric coagulation was used for the closing hemostasis. Postoperative cranial computed tomography (CT) imaging revealed no bleeding complication. Three distinct time intervals were predefined for analysis: (1) application time of MPHs, the time needed to apply the MPHs from the beginning until the powder covered the complete resection area; (2) time interval for complete hemostasis, the time interval defined from the beginning of MPH application until complete hemostasis was observed; and (3) the time interval from complete hemostasis until continuation of the procedure. This time interval differed greatly between surgeons. Some continued immediately after complete hemostasis. Others waited (up to . 10 minutes) to ensure that hemostasis was sufficient by an additional prolonged observation time. However, in no case were additional maneuvers undertaken to secure hemostasis. No additional topical agent or electrocautery was used to achieve primary hemostasis at the end of tumor resection ( Figure 3 ).
Immediately before MPH application, blood samples were taken for evaluation of differential blood count and various parameters of blood clotting. Additionally, the amount of blood loss was documented before application of MPHs and immediately postoperatively. Attention was paid to evaluate the blood loss accurately during surgery and to collect all fluid inflow and outflow. However, the blood loss could only be estimated. Thus, all blood loss measures in the Results section represent estimated values.
Follow-up Examination
Directly postoperatively, at day 1 and before hospital discharge, the patients were examined for signs of allergic reaction, embolic signs, infection, or neurological deficits. On postoperative day 1, blood samples were taken and compared with the preoperative and intraoperative results, including additional differential blood count, various hemostasis parameters, and amylolytic enzymes. Within 72 hours, early postoperative neuroradiological imaging (gadolinium-enhanced magnetic resonance imaging [MRI] scan or CT native and with contrast) was performed (Figures 4 and 5) . The follow-up examination after 3 months included neurological examination and neuroradiological imaging (MRI scan).
Data Analysis
The videos were analyzed by 2 research assistants for application time and for time interval until complete hemostasis and up to dural closure. Additionally, a hemostasis-quality evaluation scale for subjective feasibility and effectiveness of MPHs was used. The optimum amount of MPHs for effective and fast hemostasis was calculated and correlated to the tumor size. The blood sample parameters were analyzed for signs of FIGURE 2. Operative microsurgical application of microporous polysaccharide hemospheres (MPHs) to the tumor resection cavity. A and B, the 1-g Arista-AH blister. C, to apply MPH to deeper tumor resection cavities, a sterile, malleable, disposable, single-use applicator (FlexiTip) was used.
infection, blood loss, clotting function, and allergic reaction. Preoperative, early postoperative, and follow-up neuroradiological images were analyzed for tumor recurrence and signs of infection. Volume measurements were performed by segmentation of the tumor resection cavity and the intracavitary hematoma size (iPlanNet version 2.5, iPlan 3.0 cranial software; BrainLab AG, Feldkirchen, Germany). All evaluations were performed by 2 authors (M.N. and E.S.) in a blinded manner (if appropriate).
RESULTS
Patient Population
Thirty-three patients (15 female, 18 male) underwent microsurgical brain tumor resection ( Figures 4A and 5A ). Histopathologically, tumors consisted of 14 glioblastomas, 6 metastases, 5 anaplastic astrocytomas, 4 meningiomas, and 4 others ( Table 1) . Mean age at surgery was 58 years (range, 22-84 years). Nine patients underwent surgery after long-time intake of acetylsalicylic acid tablets or other anticoagulation drugs. This medication was paused 1 week before surgery. Preoperative blood samples revealed normal coagulation parameters and normal function of the liver and kidney. Preoperative clinical examination showed various neurological deficits (Table 1) .
Operative Results
Effective final hemostasis was achieved by use of MPHs without additional bipolar electrocautery or other topical hemostats in 32 patients ( Figure 3 and Video 1). In 1 patient, a single bleeding artery from the falx cerebri underwent additional bipolar coagulation (patient 28). All other bleedings from the remaining resection cavity were successfully treated with MPHs. Mean operative time was 156.8 minutes (range, 60-235 minutes). There were no intraoperative complications. Particularly, no allergic reactions were recorded, and there were no decreases or increases in blood pressure or heart rate. Blood transfusion of red blood cells was required in 5 patients (Table 2) . Of these 5 patients, 3 suffered from very large tumors, which might have contributed to the cumulative blood loss. There was no intradural blood loss after successful hemostasis was achieved with MPH application.
Analysis of the Procedure
Objective time measurements were performed by video analysis by 2 independent investigators ( Table 2 ). The mean application and hemostasis time of MPHs was 57 seconds (range, 8 to 202 seconds). In general, more MPH agent was applied in larger resection areas to achieve hemostasis. Some neurosurgeons paused the operation after hemostasis with MPHs for up to 900 seconds until dural closure. A second hemostasis was not done in any case. The dura was immediately closed in all cases.
Early Postoperative Follow-up
Postoperative blood samples were compared with preoperative and intraoperative (before MPH application) blood samples (Table 3) . No sign of infection or coagulopathy was found. Patients treated with dexamethasone showed a slight increase in white blood cell count. There was no sign of allergic reaction; the eosinophilic leukocytes showed normal values in all patients. The postoperative physical examination revealed no fever, no skin disturbances, and no other signs of infection or allergic reaction.
Follow-up Investigation
No secondary hemorrhage, infection, or allergic reaction was recorded during the follow-up period of 3 months. There were no apparent hemosphere-related postoperative neurological complications. No signs of allergic reaction or embolic complication were seen (Table 1) . In 8 patients, the ventricles were opened during surgery. In those patients, follow-up examination excluded any sign of hydrocephalus development. In 2 patients, early tumor recurrence caused neurological worsening (patients 8 and 12).
Neuroimaging
Early postoperative MRI and CT scans and 3-month follow-up scans excluded any bleeding complications. Microporous polysaccharide hemospheres were no longer detectable even as early as postoperative day 1; there was no tumor mimicking contrast enhancement (Figures 4 and 5) . The volume measurement (Table 4) in patients 3 and 27. Both patients suffered from enlarged tumors (patient 3, glioblastoma; patient 27, meningioma). However, there was a very subtle layer of clotted blood within the cavity in the vast majority of cases. In 13 of these cases, the postoperative hematoma was , 1 cm 3 (Table 4 and Figure 5B and 5C).
Hemostasis Effect of MPHs
The subjective impression of the 5 neurosurgeons was that MPHs caused very fast and sufficient hemostasis. Subjective ranking of the handling and hemostasis effect showed excellent neurosurgeon satisfaction ( Figure 6 ). To achieve full hemostasis, various doses of MPHs had to be applied. In 14 cases, the small blister of 1 g was adequate to stop the bleeding (Figure 2 ). For enlarged tumors, up to 3 g was applied (Table 2) . After the application and contact period of MPHs, no additional hemostasis was performed ( Figure 3 and Video 1). Before dural closure, the resection cavity was sometimes filled with isotonic saline solution. In 18 cases, there was no additional fluid applied to avoid flushing of the MPH powder.
DISCUSSION
Bleeding complications after brain tumor resection are observed in 0.8% to 1.5% of all procedures, 60% occurring intracerebrally, 30% epidurally, and 10% subdurally. 40 For malignant brain tumors, the bleeding risk is even higher at 1% to 4%. [41] [42] [43] [44] These secondary postoperative hemorrhages cause permanent morbidity in up to 33% of all patients with bleeding complications. 43 Especially in brain tumor surgery, diffuse bleeding can be difficult to manage and often prolongs the surgical time. Conventional hemostasis is normally done by electric tissue coagulation. Because of thermal side effects and the difficulty of coagulating diffuse bleedings, several topical hemostatic agents are in neurosurgical use. After brain tumor resection, these agents can mimic tumor relapse or infection because of gadolinium enhancement in the postoperative MRI. Additionally, granuloma formation, allergic reaction, or increased infection rates limit the application of topical hemostatic agents. a Displayed are the measured time intervals of Arista application, the hemostasis time using only Arista for the final hemostasis procedure before dura closure, and the total time of interruption of the procedure from the beginning of microporous polysaccharide hemosphere application until continuation, including a surgical pause for some individual surgeons. In the present study, full hemostasis was achieved after a mean period of 57 seconds (range, 8-202 seconds). The operative blood loss after application of MPHs was very low. In most cases, the diffuse bleeding from the resection cavity stopped immediately. For additional safety, some surgeons waited up to 15 minutes. The topical agent was rated highly effective and feasible by the performing neurosurgeons. No side effects were observed. Thus, on the basis of the very limited data of this series, the topical application of MPHs seems to be feasible for sufficient hemostasis in neurosurgical procedures. The avoidance of any diathermia application makes final hemostasis with this device potentially less invasive. Additionally, MPHs can be applied safely and easily in conjunction with bipolar electrocautery and other hemostatic agents. MPHs can easily be sucked away, and the procedure can be continued. Before definite conclusions can be drawn, some peculiarities have to be discussed, and more data should be obtained.
In 1 of 33 cases, arterial bleeding from the falx required the additional use of bipolar electrocautery. This failure might be related to the location of the bleeding vessel because the position and surface of the falx might make the adhesion of the MPH powder to the orthogonal surface difficult. However, this is just a hypothetic explanation. More data are required before any conclusions can be made. In 8 patients (25%), the ventricles were opened, and MPHs came in contact with the cerebrospinal fluid. No development of postoperative hydrocephalus was evident. Thus, the agent might also be suited for application within the cerebrospinal fluid or at the skull base. Again, more data are required before any conclusions can be drawn and definite statements can be made.
No adverse reactions such as inflammatory disease or allergic reaction have been reported for other surgical disciplines. This is further supported by the results of the present study. The postoperative MRI and CT findings revealed neither granuloma formation nor tumor or inflammation mimicking contrast enhancement caused by MPHs. Microporous polysaccharide hemospheres were not detectable in the MRI and CT scans; a rapid enzymatic absorption by the amylolytic enzyme also seems to be possible in human brain tissue. Although the risk of granuloma formation or infection has to be considered very low with other hemostatic agents, the rapid degradation of MPHs could potentially represent another advantage compared with other topical hemostats. One of the major strengths of MPH is that it is not derived from humans or animals. Thus, the risks with animal-derived products such as hypersensitivity reactions and infectious disease transmission are avoided.
Another issue with intraoperative application of any agents is their expansion in the limited intracranial space. In the present series, we have not observed any significant swelling or expansion of MPHs in any patient. However, this might still be an issue with MPH application and has to be addressed in future studies.
MPHs are inexpensive compared with other topical hemostats, particularly those of human or animal origin. With the reduced surgical time and low price, the use of MPHs could possibly be more cost-effective, although no conclusions on this issue can be drawn from the present data.
On the basis of the limited data of the present series, the primary benefits of MPH application could be a shortening of hemostasis time, a reduction of blood loss, and potentially a reduction of secondary bleeding complications after partial or total tumor resection. However, there was no head-to-head comparison with anything else. The reduction of secondary bleeding complications cannot be addressed without a proper control group. Thus, any conclusions have to be drawn carefully.
The best results might be achieved in diffuse moderate bleeding from the resection cavity walls. The white powder also allows fast visualization of remnant or recurrent bleeding. Another advantage of the technique is that no thermal side effects to healthy brain . Bar graphs of subjective ratings performed by the 5 neurosurgeons involved in this study (mean and standard deviation). The subjective rating is for handling of the microporous polysaccharide hemospheres and the applicator, impression of the hemostatic effect, and general satisfaction with the new method. 0 = useless; 1 = equivocal; 2 = useful; 3 = excellent.
tissue occur. This is especially interesting for tumor resection in eloquent areas such as the central region or speech area.
CONCLUSION
This is the first study of MPH application to human brain tissue. Microporous polysaccharide hemospheres allow very fast and effective hemostasis in brain tumor procedures. In most cases, a single application is sufficient for full and long-lasting hemostasis. No adverse reactions have been evident so far in this small series. This study should be followed by a larger prospective randomized trial to further evaluate the potential of this agent.
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